Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Presentation MaterialsTour of Manufacturing Building “FJ3” for Small and Mid-Size Molecule APIs at Fujieda Plant
Establishing the World Class Manufacturing System for
Small and Mid-Size Molecules to Drive the Realization of
TOP I 2030
Shinya Takuma,
Vice President, Head of Manufacturing Technology Div.,
Chugai Pharmaceutical Co., Ltd.
Pharmaceutical Technology for Mid-Size Molecule Drug
APIs
Dr. Kenji Maeda,
Head of API Process Development Dept., Pharmaceutical
Technology Div., Chugai Pharmaceutical Co., Ltd.
Introduction of Fujieda Plant, Chugai Pharma
Manufacturing Co., Ltd.
Kaichiro Koyama,
Head of Fujieda Plant, Chugai Pharma Manufacturing Co.,
Ltd.
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2023(Integrated Report)
What's New
-
Events & Presentations has been updated with the Date of Information Meeting on Lunsumio®
-
Script (including Q&A) for Tour of Manufacturing Building "FJ3" for Small and Mid-Size Molecule APIs at Fujieda Plant
-
Tour of Manufacturing Building "FJ3" for Small and Mid-Size Molecule APIs at Fujieda Plant
-
Notice of Convocation of the AGM of Shareholders for the Business Term ended December 31, 2024
-
Script (including Q&A) for Conference on FY 2024.12 Financial Results
-
Chugai Launches “LUNSUMIO for Intravenous Infusion,” a Bispecific Antibody for Relapsed or Refractory Follicular Lymphoma in Japan
-
Chugai Selected as “KENKO Investment for Health” for the Second Consecutive Year
-
Chugai Marks 100th Anniversary of Its Founding
-
Chugai Obtains Regulatory Approval for Tecentriq for the Additional Indication of Alveolar Soft Part Sarcoma, an Ultra-rare Disease
-
Awarded "Human Capital Leaders 2024" and "Human Capital Management Quality 2024 (Gold)" in the "Human Capital Survey 2024"
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
